2026-06-04 10:00:27
Latest Post
Alembic Pharmaceuticals Appoints Mr. Ramesh Juneja as Executive Vice President - Human Health (Sales and Marketing), India Business
Second Half Recovery Limits Nifty Losses to 78 Points; IT Index Tanks 5.5%
Akums Receives European CEP Approval for Cefpodoxime Proxetil
Tunwal E-Motors Reports Strong FY26 Results; Revenue Surges 55% to ₹276.84 Crore
Sharika Enterprises Enters High-Growth SCADA-ADMS Market with Uttarakhand Grid Modernization Project
Research
Areva T&D rating revised to Hold from Buy : Kotak Securities
Posted On : 2006-03-17 01:19:45( TIMEZONE : IST )
Kotak Securities Private Client Research has revised the rating of Areva T&D to Hold from Buy with a target price of Rs.780.